Ketoconazole (Ketoconazole HRA®). HTA ID: 21046
Ketoconazole (Ketoconazole HRA®) is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 26/10/2021 |
| Rapid review completed | 13/12/2021 |
| Rapid Review outcome | A full HTA is not recommended. The NCPE recommends that ketoconazole not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.